Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Pyxis Oncology to acquire Apexigen

Pyxis Oncology (NASDAQ:PYXS) agreed to acquire Apexigen (NASDAQ:APGN) in an all-stock transaction for an implied value of 64 cents per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares...

May 24, 2023

Developments

Wave Life flunks Phase 1b/2a study in ALS and dementia

Wave Life Sciences’ (NASDAQ:WVE) drug candidate, WVE-004, did not show clinical benefit, compared with placebo, in the Phase 1b/2a FOCUS-C9 study as an investigational treatment for C9orf72-associated amyotrophic...

May 23, 2023

Developments

T2 Biosystems exploring strategic alternatives

T2 BioSystems (NASDAQ:TTOO) initiated a process to explore a range of strategic alternatives focused on maximizing value and a restructuring plan, which includes a reduction in workforce. T2 has engaged an advisory firm...

May 23, 2023

Developments

MindBio gets ethics okay for take-home LSD-microdosing trial in MDD

MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) received ethics approval for a world’s first Phase 2a take-home LSD-microdosing clinical trial in patients with major depressive disorder (MDD) in New Zealand. The...

May 23, 2023

Markets

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...

May 22, 2023

Developments

AVROBIO to sell cystinosis gene therapy program for $87.5-million

AVROBIO (NASDAQ:AVRO) agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5-million. Cystinosis is a rare, multisystem genetic...

May 22, 2023

Developments

Hepion Phase 2 ALTITUDE-NASH trial achieves all endpoints, improvement in liver function and NASH biomarkers

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial with lead drug candidate, rencofilstat. ALTITUDE-NASH met its primary endpoint by...

May 22, 2023

Developments

Centessa receives FDA fast track in hemophilia B

The FDA granted fast track designation to Centessa Pharmaceuticals’ (NASDAQ:CNTA) SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or...

May 22, 2023

Developments

Hepion to release Phase 2 ALTITUDE-NASH results pre-market on May 22

Hepion Pharmaceuticals (NASDAQ:HEPA) expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial with its rencofilstat drug candidate before the market opens on Monday, May 22, 2023. The company...

May 19, 2023

Markets

Cantor starts Acumen Pharma at OW; PT $13

Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with an “overweight” rating and 12-month price target of $13. The stock closed at $5.45 on May 17. Acumen is a neuro-Innovator leveraging its...

May 19, 2023

Developments

HanAll BioPharma flunks Phase 3 dry eye disease trial

The Velos-3 pivotal trial of HanAll BioPharma’s (KRX:009420. KS) tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score or in...

May 19, 2023

Developments

Stereotaxis, Abbott collaborate in cardiac mapping and robotics

Stereotaxis (NYSE:STXS) and Abbott (NYSE:ABT) agreed to a global collaboration to integrate Abbott’s EnSite X EP System with its Robotic Magnetic Navigation systems. The combination brings together highly detailed real...

May 19, 2023

Pyxis Oncology to acquire Apexigen

Wave Life flunks Phase 1b/2a study in ALS and dementia

T2 Biosystems exploring strategic alternatives

MindBio gets ethics okay for take-home LSD-microdosing trial in MDD

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

AVROBIO to sell cystinosis gene therapy program for $87.5-million

Hepion Phase 2 ALTITUDE-NASH trial achieves all endpoints, improvement in liver function and NASH biomarkers

Centessa receives FDA fast track in hemophilia B

Hepion to release Phase 2 ALTITUDE-NASH results pre-market on May 22

Cantor starts Acumen Pharma at OW; PT $13

HanAll BioPharma flunks Phase 3 dry eye disease trial

Stereotaxis, Abbott collaborate in cardiac mapping and robotics

General

More